glp-1 agonist online learning resources Receptor Agonists as Treatments for Type 2 Diabetes Frontiers | GLP−1 receptor agonists
Description
Januvia offers just 2-4lbs
This case highlights the need for gradual insulin tapering and close monitoring while transitioning from insulin therapy to GIP/GLP-1 receptor agonists.
It's classic drug repurposing, a technique that saved lives during COVID.
The approval could expand access to an effective therapy for managing obesity.
Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline
